Patients taking Novo Nordisk's Wegovy obesity treatment maintained an average of 10% weight loss after four years, ...

Novo Nordisk's (NVO) obesity therapy Wegovy cut adverse kidney-related events by 22% in obese and overweight individuals in a ...

The data could potentially bolster Novo's case for Wegovy as it attempts to convince insurers and governments to cover the ...

LONDON, May 14 (Reuters) - Patients taking Novo Nordisk's popular Wegovy obesity treatment maintained an average of 10% weight loss after four years on the treatment, the company said on Tuesday. Novo ...

In a letter to Bernie Sanders, Novo Nordisk said it only retains 60% of the list price of either Ozempic or Wegovy ...

Presented at this week’s European Congress on Obesity, the two studies also demonstrate that Novo Nordisk’s Wegovy ...

Amid the growing popularity of drugs used for weight loss like Ozempic, Wegovy, Mounjaro and Zepbound, one question has ...

Patients taking Novo Nordisk's obesity drug Wegovy maintained an average of 10% weight loss for up to four years, according to a new analysis from the longest clinical trial to date on the treatment.

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Patients taking Novo Nordisk’s anti-obesity jab sustained weight loss for up to four years and had a ...

Novo Nordisk (NVO) claims it retains only 60% of list price of weight loss drugs Ozempic and Wegovy after payments to pharma ...

(Updates shares in paragraph 6, side effects in paragraph 12) By Maggie Fick LONDON, May 14 (Reuters) - Patients taking Novo Nordisk's Wegovy obesity treatment maintained an average of 10% weight ...

Certain genes may identify patients with obesity who are most likely to respond strongly to Novo Nordisk's weight-loss drug ...